Finally, in support of the same thesis and proposing a novel mechanism by which LGALS3BP might influence immune cell activation, a study published in 2014 by Läubli et al. [75] revealed that, in LS180 colorectal cancer cells, LGALS3BP was a ligand of several types of CD33-related subset acid-binding immunoglobulin-like lectins (Siglecs), often associated with the modulation of immune response to cancer. The gene discussed is LGALS3BP; the disease is cancer.